Michael J. Fox Foundation
Grifols share results identifying early signs of Parkinson’s disease
Parkinson’s disease affects over six million people globally
Mission Therapeutics advances Parkinson’s disease candidate
The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK
Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease
Planning is currently underway for a placebo-controlled trial of the candidate
Roche to advance Parkinson’s disease candidate into phase 3 development
More than ten million people worldwide are living with the neurodegenerative disorder
UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis
It is hoped that the test could be available for widespread UK use in the coming years
FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate
The progressive neurodegenerative disease affects more than ten million people worldwide
FDA approves Supernus Pharmaceuticals’ Onapgo to treat advanced Parkinson’s disease
The neurodegenerative disorder affects almost one million people in the US
AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial
More than ten million people worldwide are living with the neurodegenerative disorder
AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA
More than ten million people worldwide are living with the neurological disorder
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
Approximately 153,000 people in the UK are currently living with the neurodegenerative disorder
NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia
Patients with chronic ITP may live with an increased risk of severe bleeding events
Michael J Fox Foundation awards $4.9m grant to Muna Therapeutics
The grant will support the development of the company’s disease modifying therapy for Parkinson's disease